Loading...
01/10 19:10
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. While there are positive developments, such as the partnership with AstraZeneca and a strong cash runway, there are also concerns like missed earnings expectations, leadership transition risks, and revenue decline. The Q&A section highlights management's cautious approach, particularly in providing specific details, which may not inspire strong investor confidence. Given the lack of clear catalysts for a significant price movement and the balanced pros and cons, a neutral sentiment is justified.
Cash Balance $103.7 million, no year-over-year change mentioned.
Revenue $2.3 million, down from $2.6 million (approximately -11.5% year-over-year) due to the recognition of portions of the upfront payment and IND milestone payment from the license agreement with Gilead.
R&D Expenses $5.8 million, down from $6.4 million (approximately -9.4% year-over-year), in-line with the company's plan.
G&A Expenses $2.4 million, no year-over-year change mentioned.
Net Loss $7.2 million or $0.08 per share, slightly improved from a net loss of $7.3 million or $0.08 per share in Q1 2024 (approximately -1.4% year-over-year).
COM701: Initiated the first sub trial of our adaptive platform trial comparing COM701 maintenance therapy to placebo, in 60 patients with relapsed platinum sensitive ovarian cancer.
GS-0321: Progressing Phase 1 trial of GS-0321, a potential first-in-class anti-IL18BP antibody licensed to Gilead.
rilvegostomig: AstraZeneca has initiated three additional Phase 3 trials in lung, gastric, and endometrial cancers, with potential peak year revenues target of more than $5 billion.
Cash Position: As of March 31, 2025, approximately $103.7 million in cash, cash equivalents, and investments.
Cash Runway: Expected to fund operating plans into 2027.
Leadership Transition: Anat Cohen-Dayag transitions to Executive Chair, Eran Ophir appointed as new CEO.
Earnings Expectations: Compugen Ltd. missed earnings expectations with a reported EPS of $-0.08, compared to expectations of $-0.06.
Leadership Transition: Key leadership transitions may pose risks related to strategic direction and execution as the company adapts to new leadership.
Clinical Trial Landscape: The evolving clinical trial landscape, particularly in the TIGIT space, presents risks due to multiple Phase 3 failures, which could impact market sentiment and future opportunities.
Regulatory Risks: The company acknowledges that forward-looking statements are subject to known and unknown risks and uncertainties, including regulatory challenges.
Cash Runway: While the company has a cash runway into 2027, it does not account for any additional cash inflows, which could pose a risk if unexpected expenses arise.
Market Competition: Compugen faces competitive pressures in the immuno-oncology space, particularly with the advancement of other companies' clinical programs.
Revenue Decline: Revenues for Q1 2025 decreased to approximately $2.3 million from $2.6 million in Q1 2024, indicating potential challenges in revenue generation.
Leadership Transition: Anat Cohen-Dayag transitions to Executive Chair after 15 years as CEO, handing leadership to Eran Ophir.
Clinical Pipeline Advancement: Continued progress in early-stage and clinical immuno-oncology pipeline, including the initiation of a sub trial for COM701 in ovarian cancer.
Partnership with AstraZeneca: AstraZeneca's ongoing Phase 3 trials for rilvegostomig, with potential peak year revenues exceeding $5 billion.
Innovative Pipeline: Commitment to advancing a diverse early-stage pipeline focused on first-in-class drugs and novel mechanisms of action.
Cash Runway: Cash runway expected to fund operations into 2027, with a cash balance of approximately $103.7 million as of March 31, 2025.
Revenue Expectations: First quarter 2025 revenues were approximately $2.3 million, a decrease from $2.6 million in Q1 2024.
R&D Expenses: R&D expenses for Q1 2025 were approximately $5.8 million, down from $6.4 million in Q1 2024.
Net Loss: Net loss for Q1 2025 was approximately $7.2 million, consistent with the previous year's loss.
Cash Balance: As of March 31, 2025, Compugen had approximately $103.7 million in cash, cash equivalents, short-term bank deposits, and investments in marketable securities.
Cash Runway: The company has a cash runway expected to support its operating plans into 2027.
The earnings call reveals significant challenges: declining revenues, a shift from profit to loss, and reliance on partnerships and milestone payments. Safety concerns with anti-TIGIT antibodies and competition in the market add risks. The Q&A section highlights uncertainties in trial timelines and outcomes, further dampening sentiment. Despite potential opportunities with COM902 and a cash runway until 2027, the overall financial and strategic outlook suggests a negative market reaction.
The earnings call presents several concerns: declining revenue and increased net loss, reliance on milestone payments, and negative market sentiment in the TIGIT space. The Q&A section highlighted management's reluctance to provide details, adding uncertainty. Despite a solid cash balance, the financial outlook is weak, with decreased revenue and increased competition in the ovarian cancer treatment market. These factors suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
The earnings call presents a mixed picture. While there are positive developments, such as the partnership with AstraZeneca and a strong cash runway, there are also concerns like missed earnings expectations, leadership transition risks, and revenue decline. The Q&A section highlights management's cautious approach, particularly in providing specific details, which may not inspire strong investor confidence. Given the lack of clear catalysts for a significant price movement and the balanced pros and cons, a neutral sentiment is justified.
The earnings call summary indicates mixed signals. Financial performance shows a decline in revenue but improved net loss, while the cash runway is solid. Product development is progressing, but leadership transition and competitive pressures pose risks. The Q&A reveals cautious optimism regarding strategic opportunities and ongoing trials. Given the absence of a market cap, the stock's reaction is uncertain, aligning with a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
